Navigation Links
Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
Date:8/28/2007

on of its two key lead drugs, Albuferon for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are under way.

In June 2006, HGS announced that the U.S. government exercised its option under an existing contract to purchase 20,000 doses of ABthrax(TM) (raxibacumab) for the treatment of anthrax disease. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of hematologic and solid malignancies.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. For more information about Albuferon, please visit http://www.hgsi.com/products/albuferon.html. Health professionals or patients interested in Albuferon clinical trials or other studies involving HGS products may inquire via the "Contact Us" section of the Company's web site, http://www.hgsi.com/products/request.html, or by calling (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize prod
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Human Primary Preadipocytes and Differentiated Adipocytes
2. Low Abundance cDNA Cloned Using Stratagenes Human Universal cDNA Library
3. Control RT-PCR Primers for Human Gene Transcripts with Varying Abundance
4. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
5. Human Universal cDNA Library Array I
6. Map and Link Human Genetic Disorders with SSLP Analysis
7. RT-PCR Primer Sets for Human and Mouse Mismatch Repair Genes
8. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
9. Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations
10. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
11. Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression Vector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  EMD Serono today announced the US biopharmaceutical ... , appointed Alise Reicin , MD, ... Development.  Dr. Reicin brings extensive research and early/late ... Immunology. She is an accomplished pharmaceutical executive with ... President in various capacities across R&D at MSD ...
(Date:4/16/2015)... and MENLO PARK, Calif. , April ... DMPI) (DelMar and the Company), a biopharmaceutical company focused ... orphan drug indications, today announced that the Mayo ... clinical trial site for the ongoing, multicenter Phase I/II ... (GBM), the most common and deadly form of human ...
(Date:4/16/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... DCVax® personalized immune therapies for cancer, announced today ... Cancer Immunotherapy Index (LCINDX), a professional index recently ... field within the biotechnology space.  ... companies" in the immunotherapy space, including 6 big ...
(Date:4/16/2015)... Tex. (PRWEB) April 16, 2015 ... chain management systems for highly regulated industries, is ... been name a monthly columnist for Cold Chain ... ( http://www.coldchainiq.com ). His column titled, Global Cold ... chain information for today’s life sciences, pharmaceutical and ...
Breaking Biology Technology:Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... April 12, 2011 Reportlinker.com announces that a new ... Biomarker Partnering Terms and Agreements ... The Biomarker Partnering Terms and Agreements report ... partnering deals and agreements entered into by the worlds ...
... April 11, 2011 Shrink Nanotechnologies, Inc. ("Shrink") (OTC ... that it has executed a binding letter of intent ... biomedical instrumentation and microfluidics company with global distribution for ... The transaction highlights are: Shrink ...
... Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), ... development, manufacture and sale of enzyme and protein ... industries, today announced that its President and Chief ... Advanced Biofuels Leadership Conference taking place from April ...
Cached Biology Technology:Reportlinker Adds Biomarker Partnering Terms and Agreements 2Reportlinker Adds Biomarker Partnering Terms and Agreements 3Reportlinker Adds Biomarker Partnering Terms and Agreements 4Reportlinker Adds Biomarker Partnering Terms and Agreements 5Reportlinker Adds Biomarker Partnering Terms and Agreements 6Reportlinker Adds Biomarker Partnering Terms and Agreements 7Reportlinker Adds Biomarker Partnering Terms and Agreements 8Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 2Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 3Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 4Dyadic International to Present at Advanced Biofuels Leadership Conference 2
(Date:3/23/2015)... OXFORD, Conn. , Mar. 23, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, announces ... a new advertising campaign on CNBC television starting March 30 ... ads will commence airing in New York ... Executive Officer said: "We are excited about our new ad ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... 17, 2015 Emotient, the leader in ... announced general availability of Emotient Analytics , ... analysis of facial expressions. The system analyzes videos ... products and services. It delivers audience response metrics ... - as derived from facial evidence of emotional ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... discovery made by researchers at the Institut de recherches ... Di Noia, Director of the Mechanisms and Genetic Diversity ... Journal of Experimental Medicine . The team identified a ... for the therapy of some types of lymphoma and ...
... State University are developing a cost-effective electronic monitoring system ... critical coastal ecosystems by allowing users to track water-quality ... support from a National Science Foundation (NSF) grant. ... to monitor environmental conditions in the Chesapeake Bay, the ...
... London, UK (November 1, 2010) In April 2010, ... on the conclusion that the current missile defense systems will ... of nuclear-armed combat. Now research in the Bulletin of ... have not been tested against real-world threats and would not ...
Cached Biology News:A discovery could be important for the therapy of lymphoma and leukemia 2Researchers developing real-time electronic monitoring for coastal waters 2US nuclear safety claim is a 'dangerous fantasy' 2US nuclear safety claim is a 'dangerous fantasy' 3